Ultralow-dose 18F-FDG PET imaging with a high-sensitivity scanner

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study uses a very small amount of the standard 18F-FDG tracer (under 1/20th of the usual dose) and a new high-sensitivity PET scanner to acquire images over periods up to three hours. Investigators will vary injection-to-scan timing, scan duration, and image reconstruction methods to optimize image quality at dramatically reduced radiation levels. Approximately 200 adults, including healthy volunteers and people with cancer, will be imaged at the Nuclear Imaging Institute. The primary goal is to determine whether diagnostically useful images can be produced with a 10- to 100-fold reduction in radiation dose compared with current clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. Ability to provide informed consent and comply with study procedures.
3. For female participants:

   * Must not be pregnant or breastfeeding.
   * Negative pregnancy test required for women of childbearing potential.

Exclusion Criteria:

1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
2. More than four prior enrollments in this study.
3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
4. Medication \& Prior Treatment Exclusions
5. Pregnant or breastfeeding individuals (negative pregnancy test required)
6. Inability to provide informed consent
7. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.

Where it's running

• Nuclear Imaging Institute
  Englewood, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Barbara Blanchfield
• Email: bblanchfield@nii.org
• Phone: 973-255-4955

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake

  This study will test whether an ultralow-dose 68Ga-Dotatate PET scan on a high-sensitivity scanner can detect SSTR2 uptake in adults with and without neuroendocrine tumors.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT07284589

• Ultralow-dose PET scan to detect bone activity with 18F‑NaF

  This trial tests whether a new high-sensitivity PET scan using a tiny amount of 18F‑sodium fluoride can produce clear bone images in adults with or without bone disease while cutting radiation exposure by 10–100 times.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey and 1 other locations · NCT07284563

• Ultralow-dose amyloid PET with 18F‑Florbetapir or 18F‑Flutemetamol

  This trial will try using a very small amount of an amyloid PET tracer with a high-sensitivity PET scanner to see if clear brain images can be made for people with Alzheimer’s, mild cognitive impairment, other dementias, and healthy volunteers.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT07012993

• Ultralow-dose PET imaging for PSMA expression in prostate cancer

  This test will try to see if an ultralow-dose PET scan using 18F-DCFPyL can detect PSMA in people with and without prostate cancer while cutting radiation exposure by 10- to 100-fold.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT06904313

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.